Variations in measured ER, PR, and HER2 status in synchronous and asynchronous paired breast cancer (BC) tumors


Clayton Yates1, Sherri Z. Millis2, William L. Gluck3, Zoran Gatalica2, Sandeep Reddy2, Joyce O’Shaughnessy4, Windy M. Dean-Colomb5

Background: That tumor heterogeneity exists and evolves over time is well appreciated but how often to biopsy patients’ metastatic BC is not well established.
Methods: Immunohistochemical (IHC) and in situ hybridization (ISH) analysis of estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), and HER2 in 337 cases with >1 asynchronous primary/metastatic BC molecular profiles and in 40 cases with >1 synchronous molecular profiles was performed at a single institution.

We evaluated differences in ER, PR and HER2 status in same or contralateral breast, and in primary vs. locally recurrent or metastatic BC’s.

Download Publication